Na^(188)ReO_4、^(188)Re-DTPA和^(188)Re-MAG_3的生物分布及排泄比较

Comparison of Na^(188)ReO_4,^(188)Re-DTPA and ^(188)Re-MAG_3 on Biodistribution and Excretion of Animal

为比较Na188ReO41、88Re-DTPA和188Re-MAG3在冠状动脉再狭窄防治中的优劣,将这三种放射性药物注入到ICR小鼠和SD大鼠体内,观察其在小鼠体内的分布及在大鼠体内的排泄动力学。结果显示,188Re-MAG3在小鼠体内的血液清除明显快于188Re-DTPA和Na188ReO4,并且在各主要组织脏器的吸收也明显低于188Re-DTPA和Na188ReO4。注射后2 h,77.28%的188Re-MAG3经尿液排出体外,而此时188Re-DT-PA和Na188ReO4的尿液排出量不到注射剂量的50%1。88Re-MAG3在动物体内的行为明显优于188Re-DTPA和Na188ReO4,更适于冠状动脉再狭窄的防治。

In order to screen out an ideal radioactive agent for preventing the restenosis after PTCA （Percutaneous Transluminal Coronary Angioplasty）, Na^188 ReO4, ^188Re-DTPA and ^188Re-MAG3 are injected into ICR mice and SD rats to compare the biodistribution and excretion. The experimental data show that the blood clearance of ^188Re-MAG3 is much faster, and the uptake in tissues is obviously lower than Na^188ReO4 and ^188Re-DTPA . At 2 h after injection, 77.28% of injection dose of ^188Re-MAG3 is excreted from urine, whereas less than 50% for Na^188ReO4 and ^188Re-DTPA. So, ^188Re-MAG3 is a better candidate for balloon dilation providing uniform endovascular irradiation following PTCA for restenosis therapy.